Objective: To investigate trajectories of cognitive decline in patients with different types of dementia compared to controls in a longitudinal study.
Introduction
The most common causes of dementia are characterised by specific profiles of cognitive impairment. Alzheimer's disease (AD) is characterized by prominent episodic memory impairment, while in other types, other domains are more primarily affected, i.e. executive functioning in vascular dementia (VaD) [1] . Trajectories of cognitive decline in different types of dementia in a single cohort have hardly been studied. Most studies were not longitudinal, which limits interpretation of results. Studies with a longitudinal set-up were frequently limited to the Mini-Mental State Examination (MMSE) as a cognitive measure [2, 3] . Since the MMSE is a global screening test, no domain specific conclusions can be drawn. Furthermore, the single focus of most studies is AD instead of various types of dementia, making it hard to compare different types of dementia.
Two earlier longitudinal studies investigated decline on several neuropsychological tests in various types of dementia [4, 5] . One study focussed on semantic memory tests and used patients with semantic dementia as a reference group [4] . They found that all types of dementia performed worse than controls and AD showed a similar, but milder pattern of impairment of semantic memory than as semantic dementia. The other study focused on three domains; executive functioning, language and visuo-construction in four subtypes of frontotemporal lobar degeneration (FTLD). They concluded that diverse neuropsychological patterns of FTLD-subtypes continue to exist [5] .
We investigated decline in global cognition and five cognitive domains for five types of dementia compared to controls. We aimed to provide better insight in the trajectories of cognitive decline over time in different types of dementia. We expected that every type of dementia would particularly show decline in those cognitive domains that are associated with the brain areas most prominently involved in each type of dementia.
Methods

Subjects
We included 270 patients with a diagnosis of dementia and at least two visits including neuropsychological evaluations (baseline and follow up) from the Amsterdam Dementia Cohort at the Alzheimer Center of the VU University Medical Center Amsterdam, between January 2004 and December 2011 [6] . Patients with available follow-up were younger (65±8 versus 69±9), less often female (41% versus 51%), had higher education (5±1 versus 4.7±1), had higher MMSE-scores (22±4 versus 19±6) than 384 persons who presented during the same time period, but who received no follow-up (all p<0.05).
All patients underwent a standardized one-day assessment including medical history, informant-based history, physical and neurological exam including Clinical Dementia Rating, neuropsychological assessment and the Geriatric Depression Scale (GDS), laboratory tests, magnetic resonance imaging of the brain and electroencephalogram. The duration of the cognitive complaints as reported by the patient and / or caregiver was recorded to estimate the disease duration at time of diagnosis. Diagnoses were made in a multidisciplinary consensus meeting using international diagnostic consensus criteria. For a diagnosis of probable AD (N=199) patients had to fulfil the diagnostic criteria of McKhann [7, 8] , for vascular dementia (VaD), (N=10) the NINDS-AIREN criteria [9] , for DLB (N=26) the criteria of McKeith [10] , for behavioural variant frontotemporal dementia (bvFTD) (N=20) the criteria of Neary or Rascovsky [11, 12] and for language variant frontotemporal dementia (lvFTD; N=15, including nonfluent progressive aphasia (N=7) and semantic dementia (N=8)) the criteria of Neary or Gorno-Tempini [11, 13] .
In addition, we included 112 patients with subjective complaints who served as controls. Patients were considered to have subjective cognitive complaints when they had normal laboratory investigations and did not have other known causes of cognitive complaints. Their performances on neuropsychological tests, corrected for age, education or sex, were normal. Furthermore, patients with subjective complaints were only included when they did not progress to MCI or dementia within the study period. Pharmalogical treatment for dementia was registered: 11 patients with AD used Galantamine and 16 patients were treated with Rivastigmine (12 AD, 3 DLB and one bvFTD). Level of education was classified according to the system of Verhage ranging from 1 to 7 (low to highly educated) [14] . The local Medical Ethics Committee approved the study and all patients gave written informed consent for their clinical data to be used for research purposes. Table 1 summarizes the baseline demographics of the diagnostic groups. In general, patients were older (65±8 years) and lower educated (5.0±1) than controls (61±8 and 5.5±1; both p<0.001). On the MMSE, patients with dementia scored lower than controls (all p<0.05). Patients with AD had the lowest MMSE-score (22±4). Table 2 lists the raw baseline neuropsychological test performance of controls and patients with different types of dementia. We conducted linear mixed models to compare the trajectories of cognitive decline as measured by a comprehensive neuropsychological test battery between patients with different types of dementia and controls.
Results
For the estimated effects, see table 3. In general, patients with a diagnosis of dementia performed worse than controls at baseline on all cognitive domains, except for visuo-spatial functioning, which was only impaired in AD and DLB. Table 4 summarizes the estimated annual cognitive decline for the different dementia groups, compared to controls in schematic overview. Executive functioning Visuo-spatial functioning Table 4 . Schematic overview of estimated trajectories of cognitive decline for patients with dementia, compared to controls. patients had a diagnosis of VaD, which was primarily a diagnosis of post-stroke dementia. In contrast, the diagnosis of all of our VaD patients was supported by brain imaging, mostly small vessel disease.
AD
The diverse patterns of cognitive decline could not be explained by differences in disease duration at baseline or on the Clinical Dementia Rating, although we found differences on MMSE. At baseline, patients with AD performed worse on the MMSE and one might interpret that these patients are cognitively more impaired.
However, the MMSE is known to rely heavily on memory, the domain on which AD most was impaired [35] .
Besides memory it relies on language, patients with bvFTD declined fastest on language and memory and this might be reflected in their fast decline on MMSE. As a consequence, the MMSE might have some restrictions when it is used to compare global cognition in different types of dementia.
A possible limitation of this study is that, except for AD and controls, sample sizes are relatively small. On the other hand, longitudinal studies on non-AD dementias are scarce, and for these more rare types of dementia, our group sizes are in fact not so small. We feel that even when reported significance levels are limited by suboptimal power, reporting effect sizes of these groups is very valuable. Our results need to be replicated in larger studies.
The sample described in our study is relatively young, which might limit generalizability to dementia in general.
Nonetheless, we feel that the relative young age has also advantages, as non-AD types of dementia often develop at a younger age and as such we were able to include diverse types of dementia. In addition, dementia at a younger age is often thought to be more pure, and less mixed pathology, hence the patterns of decline may be more specific. Amongst the strengths of our study is the longitudinal set-up and the comprehensive neuropsychological assessment covering five cognitive domains.
Our findings have large impact, as they provide estimates of natural disease course in different types of dementia.
Clinical trials have thus far most frequently used global outcome measures including the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog) [36] , Clinical Dementia Rating, questionnaires about activities of daily living and behaviour. Shortcomings of the ADAS-Cog includes its primary focus on memory and language, while tasks assessing attention, executive or visuo-spatial functioning are not incorporated in the test [37] . More extensive neuropsychological assessments covering several cognitive domains, like the Neuropsychological Test Battery, are increasingly being preferred over the ADAS-Cog. These neuropsychological batteries are better in detecting subtle cognitive changes and therefore seem more suitable for cognitive assessments in trials in preclinical/early disease stages. Recently, the Food and Drug Administration proposed to revise the criteria for drug approval since persons in very early disease stages have no obvious deterioration in daily functioning. They suggested that in trials (in very early stages of disease) cognitive tests should be used as end-points [38] . In addition, clinical trials are currently designed for other types of dementia than AD. Therefore, estimates of cognitive trajectories of different types of dementia are essential for trial design and power calculations.
